X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Peli BioThermal Announces Latest Distributor Partnerships

Content Team by Content Team
3rd March 2021
in News, Packaging & Logistic
Peli BioThermal Announces Latest Distributor Partnerships

Peli BioThermal, the global name in temperature controlled packaging, announces additional distributor partnerships expanding the company’s growing global network. Peli BioThermal continues to expand its worldwide distributor base providing comprehensive customer convenience with the announcement of commercial collaborations with Sharkmed Oy in Finland and Corena Pharmaceutical Wholesaler located in Turkey.

Paul Terry, Director of Sales EMEA at Peli BioThermal, said: “We are delighted to be working with our new distributors who are operating in these key European locations. These additions further enhance Peli BioThermal’s growing global footprint, providing customers greater access to our full portfolio of high-performing products, including our deep frozen product range, which was recently expanded to support the ongoing response to the global pandemic.” Sharkmed Oy and Corena Pharmaceutical Wholesaler https://www.corena.com.tr/ will both offer customers access to Peli BioThermal’s comprehensive range of products.

Founded in 2000, Sharkmed Oy specialises in supplying essential equipment to Emergency Medical Services, particularly Tactical Combat Casualty Care, alongside providing training in personal and fire safety. Based in Hyvinkaa, southern Finland, the company is also a long established distributor of high-performing cases provided by Peli BioThermal’s corporate parent, Peli Products. Established in 1998 with its own robust service network, Corena Pharmaceutical Wholesaler supplies to 86 countries on six continents. The company is based in Turkey’s capital Ankara and specialises in the provision of pharmaceuticals and medical supplies internationally.

About Peli Products
Peli Products, S.L.U. is the global leader in the design and manufacture of high performance protective cases, temperature-controlled packaging solutions, advanced portable lighting systems and rugged gear for professionals and outdoor enthusiasts. Their products are used by professionals in the most demanding markets including fire safety, law enforcement, defense / military, aerospace, entertainment, industrial and in numerous outdoor markets. Peli™ products are designed and built to last a lifetime. Headquartered in Torrance, CA, Pelican Products, Inc. operates in 26 countries, with 24 international sales offices and six manufacturing facilities across the globe.

About Peli BioThermal
Peli BioThermal Ltd. offers the widest range of temperature controlled packaging and service solutions to the global life sciences industry. The company is the recipient of two Queen’s Awards for Enterprise: International Trade in 2018 and Innovation in 2017. The company’s
products ensure that delicate biological materials arrive intact and effective, despite exterior environments. Peli BioThermal is dedicated to developing innovative products designed to fulfil the complex needs of the global life sciences industry. The company’s customers benefit
from its extensive expertise in ensuring that temperature stability is maintained throughout the distribution chain. The company also offers a complete portfolio of services and software to support end-to-end temperature-controlled packaging asset management. Outside of Europe, the company does business under the name Pelican BioThermal LLC.

Previous Post

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

Next Post

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

Related Posts

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials
News

NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials

3rd March 2021
DHL expands pharma capabilities in South Africa
News

DHL Express partners with MASkargo to deliver first batch of Covid-19 vaccines to Malaysia

3rd March 2021
Full service: the expertise and efficiency of a one-stop shop
Drug Development

Full service: the expertise and efficiency of a one-stop shop

26th February 2021
Vetter continues its successful performance at the 2021 CMO Leadership Awards
News

Vetter continues its successful performance at the 2021 CMO Leadership Awards

25th February 2021
Next Post
Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

Latest News

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment
Press Statements

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

16th March 2021
Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Press Statements

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

3rd March 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In